Date: Fri 23-Apr-1999
Date: Fri 23-Apr-1999
Publication: Hea
Author: KAAREN
Quick Words:
FDA-Lyme-immunization-LYMErix
Full Text:
HEALTH MONITOR: FDA Approves First Lyme Disease Vaccine
BY ANDREA ZIMMERMANN
After more than a year of trials, the FDA has approved the world's first Lyme
disease vaccine which is designated for people aged 15-70 who frequent areas
infested by Borrelia burgdorferi-infected ticks. Manufactured by SmithKline
Beecham Biologicals, the immunization is given in a series of three
injections. Although the FDA approved the vaccine to be administered over a
year's period, area hospitals and local physicians offer an accelerated
series, because Lyme disease "season" is upon us.
"We are in an endemic area and studies showed the vaccine did not adequately
protect a person until the third shot," says Jennifer Holloway, MD, an
internist who is in practice with Peter Licht, MD, in the Newtown Professional
Center. The doctors offer a three-month series of vaccines.
Between 1982 and 1996, more than 99,000 cases of Lyme Disease were reported to
the nation's Centers for Disease Control. In 1996, Connecticut had the highest
rate of reported cases (91.5 per 100,000 population). Danbury Hospital was one
of the trial sites for the vaccine; now, it also offers the series.
"Unlike typical vaccines, LYMErix can fight the bacterium while the germ is
still inside the tick, before the patient becomes infected. When the tick
sucks a vaccinated person's blood, it will ingest the antibodies, which can
neutralize Lyme germs inside the tick," reported Charles Henderson in Vaccine
Weekly last January.
Average cost for the vaccine is $65 per shot; in addition, one office visit
fee may be charged. The first two shots in the series are given one month
apart; the third is at 12 months from the first vaccine. If an accelerated
course is chosen, patients can complete the schedule within two to three
months. (The latter course has not been studied extensively and is not yet
approved by the FDA.) The vaccine is genetically engineered and cannot cause
Lyme disease; it does not contain any bacterial products.
It is unknown how long the vaccine will protect and when, if any, booster is
needed. Also, the FDA cautions the vaccine does not prevent all cases of Lyme
disease. The vaccine has an efficacy against confirmed Lyme disease of 50
percent after two shots and 78 percent after three. (These numbers reflect
results of trials where the vaccine was administered between January and April
-- before the height of transmission season.) Against asymtomatic infection,
two injections are reported to be 83 percent effective and the full-series 100
percent effective.
"I am hopeful we can prevent Lyme in many people by this vaccine," says Dr
Holloway. "But it's not foolproof."
The physician encourages people to learn about the vaccine, evaluate their
risks for infection, and then make their own decisions about whether or not to
have the vaccine. The reason Dr Holloway is not encouraging all of her
patients to have the vaccine is because the long-term side-effects are not
known. Usually, Lyme disease can be cured with antibiotics, but left untreated
the disease can severely damage the nervous system and heart. And there are
instances where some people experience residual chronic Lyme, says Dr
Holloway. Those suffering from advanced arthritis caused by Lyme are not
candidates for the vaccine, she added. But others who have previously been
infected can reap the same benefits as those who have not.
Adverse reactions to the vaccine include flu-like symptoms, myalgias,
arthralgias, rash, joint and muscle pain, and possible redness and swelling
around the site of vaccine injection. The side effects usually appear and
vanish within the first four days after injection. Most insurance companies
cover the cost of the vaccine series, although Medicare does not, says Dr
Holloway.
Now that the FDA has approved the vaccine, SmithKline Beecham will conduct a
study in New England to obtain further safety data on its product, and do
animal testing to establish a pregnancy registry. Right now, the vaccination
is available only through physicians. Recommendations for the use of the
vaccine are being developed by the Advisory Committee for Immunization
Practices.
But even if you have the new Lyme vaccine series, don't drop your guard. Both
physicians and LYMERix manufacturers suggest you continue to take the
following traditional precautions. And remember to protect children; they are
not yet candidates for the vaccine and, according to Connecticut state lab,
those five to nine years old are most likely to contract Lyme disease.
Wear long pants and tuck pant legs into socks. Also, tuck your shirt into your
pants. Wear clothes made of tightly-woven materials.
Pull back long hair.
Wear a hat.
Avoid sitting directly on the ground. Use a light-colored blanket which has
been treated with repellent.
Spray clothes and exposed skin with a repellent containing DEET (read cautions
first)
Avoid walking in brushy areas.
Clear tall grass or brush from your property.
Inspect clothing and skin every 3-4 hours when you are outside (also check
pets). When you come in, inspect your body thoroughly for ticks.
Wash "outdoor" clothes in hot water and dry on high.
Shower immediately after coming inside.
Infected ticks must be attached to the skin for 24 hours to transmit Lyme
disease, according to Dr. Holloway. If you are not certain how long a tick has
been attached to the skin, many local health departments will send suspect
ticks removed from humans to the state lab for testing.
For more information on the Lyme Disease vaccine, contact your physician,
health department, or visit the LYMErix Web site at www.lymerix.com.